title: Simvastatin: building on success.
abstract: Over a decade after launch, simvastatin remains the most widely-prescribed statin in the UK. This has resulted from a growing body of long-term outcome data, a steadily expanded range of indications, an extended dose range and proven cost-efficacy.
authors.affiliation: Department of Pathological Biochemistry, Glasgow Royal Infirmary, Glasgow G4 0SF.
authors.forename: A
authors.initials: A
authors.lastname: Gaw
mesh_terms: D000368:Aged; D003327:Coronary Disease / Q000188:drug therapy* / Q000191:economics; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000191:economics / Q000627:therapeutic use*; D008297:Male; D019821:Simvastatin / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000960:Hypolipidemic Agents; D019821:Simvastatin